Danish Oil and Gas Stock News

GN Store Nord's latest Annual General Meeting approved the Annual Report and confirmed no dividend distribution for the period. Shareholders authorized the company to buy back treasury shares, subject to defined limits. The meeting also introduced new employee elected board members, replacing previous representatives. For GN Store Nord (CPSE:GN), these decisions come after a tough period for the share price. It is at DKK89.0 and has seen a 24.2% decline over the past year and an 81.2%...

Why Danske Bank (CPSE:DANSKE) is drawing fresh attention Recent share price moves in Danske Bank (CPSE:DANSKE), including a decline over the past month along with a gain in the past 3 months, are prompting investors to reassess the bank’s current valuation and fundamentals. See our latest analysis for Danske Bank. The recent 1 month share price return of a 5.72% decline and 7 day softness sit against a year to date share price return of 1.16%. At the same time, the 1 year total shareholder...

ALK-Abelló (CPSE:ALK B) shares are in focus after the company reported new EURneffy user data at the AAAAI 2026 meeting, with 88% of trial participants preferring the needle free nasal adrenaline treatment to auto injectors. See our latest analysis for ALK-Abelló. The AAAAI data arrive after a softer patch for the shares, with a 1 day share price return of a 2.01% decline and a 7 day share price return of a 4.04% decline, even though the 1 year total shareholder return is 55.41% and the 3...

Vestas Wind Systems (CPSE:VWS) has just secured a firm order to supply, deliver, commission, and subsequently service 92 V236-15.0 MW turbines for RWE’s 1,380 MW Vanguard East offshore project in the United Kingdom. See our latest analysis for Vestas Wind Systems. Despite the new Vanguard East contract and recent agreements such as the MoU with DENZAI K.K., Vestas Wind Systems’ DKK159.35 share price has a year-to-date share price return of a 10.8% decline, while the 1-year total shareholder...

Investors are refocusing on Novo Nordisk (CPSE:NOVO B) after it resolved a legal clash with Hims & Hers Health and agreed to sell branded Ozempic and Wegovy through the telehealth platform at self pay prices. See our latest analysis for Novo Nordisk. That truce with Hims & Hers comes after a tougher spell for shareholders, with a 30 day share price return of 19.7% and a 1 year total shareholder return decline of 49.4%, signalling fading momentum despite a series of GLP 1 focused partnerships,...

Dampskibsselskabet Norden (CPSE:DNORD) held its AGM on 11 March 2026, approving a final 2025 dividend of DKK 2.00 per share and adopting share capital reduction amendments that directly affect the company’s capital structure. See our latest analysis for Dampskibsselskabet Norden. At a share price of DKK291.6, Dampskibsselskabet Norden has registered a 30 day share price return of 8.97% and a year to date gain of 16.36%. The 1 year total shareholder return of 63% contrasts with a 25.14% total...

Jyske Bank (CPSE:JYSK) is in the middle of a sizeable share buyback, planning to repurchase up to DKK 3b of stock by January 2027, with treasury shares already approaching 6% of capital. See our latest analysis for Jyske Bank. At a share price of DKK904.0, Jyske Bank has seen a 7.61% 1 month share price decline after a 10.38% 3 month share price gain. Its 1 year total shareholder return of 63.72% and 5 year total shareholder return of 245.20% point to strong longer term compounding, with the...

A.P. Møller - Mærsk (CPSE:MAERSK B) has temporarily suspended several shipping services connecting the Middle East with Europe and Asia, after the closure of the Strait of Hormuz created fresh security and fuel distribution challenges. See our latest analysis for A.P. Møller - Mærsk. The latest news comes after a choppy period for the stock. The 1-day share price return shows a decline of 1.39% and the 7-day share price return shows a decline of 5.88%. This is set against a 30-day share price...

NKT (CPSE:NKT) has secured its largest single cable contract, a firm agreement worth more than €2.2b for the Eastern Green Link 3 HVDC project in the UK. This deal expands the company’s high voltage order backlog. See our latest analysis for NKT. NKT’s EGL3 contract and recent decision to refinance its subordinated capital securities come against a backdrop of firm share price momentum, with a 1 day share price return of 3.3%, a 7 day share price return of 8.4%, and a 1 year total shareholder...

Share buy-back puts Alm. Brand (CPSE:ALMB) in focus Alm. Brand (CPSE:ALMB) has drawn fresh investor attention after announcing a share buy-back program of up to DKK 835.2 million, with the company now holding 3.44% of its own shares. See our latest analysis for Alm. Brand. At a share price of DKK16.34, Alm. Brand has seen a 1-day share price return of 1.24% and a 7-day share price return of 2.57%, although the 30-day and year-to-date share price returns of 4.28% and 12.15% declines suggest...

If you are wondering whether Danske Bank shares still offer value after a strong run, this article walks through what the current price might be implying about the company. The stock last closed at DKK 325.30, with returns of 2.7% over 7 days, a 4.4% decline over 30 days, 1.8% year to date and 48.2% over 1 year, while the 3 year and 5 year returns stand at 169.7% and 239.3% respectively. Recent headlines around Danske Bank have focused on its position among Nordic lenders and how investors...

Novo Nordisk (CPSE:NOVO B) has resolved its legal dispute with Hims & Hers Health over compounded GLP-1 weight loss treatments. The two companies have entered a new commercial partnership for Hims & Hers to distribute Novo Nordisk's branded weight loss drugs, including Ozempic and Wegovy, via its telehealth platform. As part of the agreement, Hims & Hers will stop promoting compounded GLP-1 products, focusing instead on Novo Nordisk's FDA approved therapies. Novo Nordisk, known for its...

How Novozymes Shares Have Been Performing Novozymes (CPSE:NSIS B) has been under pressure recently, with the stock showing a 2.3% decline over the past day and deeper pullbacks over the past week, month, and past 3 months. Over the past year, Novozymes has delivered a total return of 9.6%. The year to date move reflects a 10.5% decline. Looking at longer periods, the 3 year total return stands at 11.9%, and the 5 year total return shows a 4.0% decline. See our latest analysis for...

CEO change puts fresh focus on Coloplast shares Coloplast (CPSE:COLO B) is back in focus after the board named Gavin Wood as President and CEO, effective May 1, 2026, following a period under interim chief Lars Rasmussen. See our latest analysis for Coloplast. The CEO announcement comes after a weaker run for the shares, with a 7 day share price return of 7.04% and a 90 day share price return of 20.51%. This has contributed to a 1 year total shareholder return of 37.52% and a 5 year total...

A.P. Møller - Mærsk recently suspended key container services linking the Middle East with Europe and Asia, along with Gulf shuttle operations, and altered its ME1 rotation to bypass Jebel Ali as it responds to heightened security risks in the region. This shift reroutes cargo away from a major Middle Eastern hub, potentially reshaping how global shippers manage transit times, capacity, and supply chain resilience across these trade lanes. We’ll now examine how this temporary suspension of...

Aktieselskabet Schouw (CPSE:SCHO) just reported full year 2025 results, pairing lower net income with a higher proposed dividend and strong cash flow. This combination gives you several angles to assess the stock. See our latest analysis for Aktieselskabet Schouw. These results land after a weak run in the share price, with a 7 day share price return of 7.60% and a 30 day share price return of 10.40%. However, the 1 year total shareholder return of 4.31% and 3 year total shareholder return of...

Zealand Pharma (CPSE:ZEAL) is under close watch after Phase 2 topline data for obesity drug candidate petrelintide triggered a sharp share price drop, despite meeting the trial’s primary weight loss and safety goals. See our latest analysis for Zealand Pharma. The sharp 1 day share price return of 36.4% and 7 day share price return of 36.1% have reversed much of Zealand Pharma’s earlier gains. However, the 3 year total shareholder return of 4.9% and 5 year total shareholder return of 23.7%...

Earnings jump puts UIE (CPSE:UIE) in focus UIE (CPSE:UIE) is back on the radar after reporting full year 2025 earnings, with sales of US$587.28 million and net income of US$139.92 million, alongside basic EPS of US$4.48 from continuing operations. See our latest analysis for UIE. The earnings release comes after a mixed period for the shares, with a 1-day share price return of 0.98% and 7-day share price return of 0.84%. This is set against a 30-day share price return of 4.50% and year to...

If you are wondering whether Aktieselskabet Schouw is attractively priced right now, the starting point is to separate what the share price is doing from what the underlying value might suggest. The stock last closed at DKK 634.0, with returns of a 6.4% decline over 7 days, a 6.1% decline over 30 days, a 4.5% decline year to date, and a 5.8% gain over 1 year, a 20.5% gain over 3 years, and a 10.1% gain over 5 years. Taken together, this gives you a mixed picture of recent sentiment over...

Maersk, ticker CPSE:MAERSK B, has temporarily suspended multiple key shipping routes to and from the Middle East. The halt affects links between the Middle East and Europe as well as Asia, in response to escalating conflict and security concerns. These adjustments touch several major services and ports that form part of Maersk’s global container network. A.P. Møller – Mærsk is one of the world’s largest container shipping and logistics groups, so route suspensions of this scale can matter...

Zealand Pharma reported positive Phase 2 topline results for petrelintide, its obesity drug candidate, with clinically meaningful weight loss and strong tolerability. The trial met its primary weight reduction endpoint and showed a favorable safety profile, according to the company. The news has arrived as investors reassess Zealand Pharma’s position in the obesity drug space and its collaboration with Roche. For holders of CPSE:ZEAL, the latest petrelintide data lands after a sharp reset...

Scandinavian Tobacco Group (CPSE:STG) has wrapped up FY 2025 with fourth quarter revenue of DKK 2,343.3 million and basic EPS of DKK 2.10, set against trailing 12 month revenue of DKK 9,035.7 million and EPS of DKK 8.5. Over recent quarters the company has seen revenue move from DKK 2,457.5 million in Q4 2024 to between DKK 2,361.4 million and DKK 1,973.7 million through the first three quarters of 2025. Quarterly EPS ranged from DKK 0.7 to DKK 2.9, leaving investors focused on how the latest...

Netcompany Group (CPSE:NETC) is back in focus after its fully electronic Annual General Meeting on 5 March 2026, where shareholders approved a share capital reduction, no dividend for 2025, and amendments to the Articles of Association. See our latest analysis for Netcompany Group. Those AGM decisions come as the share price sits at DKK337.4, with a 1 day share price return of 1.69% and a 7 day share price return of 4.39%. The 1 year total shareholder return of 14.45% contrasts with a 5 year...

Bavarian Nordic CEO Paul Chaplin is set to step down after a period of transformational leadership. The leadership change follows a recently failed acquisition bid that had aimed to reshape the company. The transition comes alongside turnover at the chairman level, marking a broad shift at the top of the organization. Bavarian Nordic, traded as CPSE:BAVA, enters this leadership transition with its shares at DKK187.6. The stock is up 12.0% over the past year, but shows declines of 4.7% over...